TB drug discovery: Addressing issues of persistence and resistance

Tuberculosis

Volumn 84, Issue 1-2, 2004, Pages 45-55

  Smith, Clare V ^a   Sharma, Vivek ^b   Sacchettini, James C ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cyclopropane synthase; Glyoxylate shunt; Isocitrate lyase; Malate synthase; Mycolic acid; Persistence; Potential drug target; Resistance; Structure based drug design; Tuberculosis

Indexed keywords

CYCLOPROPANE SYNTHASE; GLYOXYLIC ACID; ISOCITRATE LYASE; ISONIAZID; MALATE SYNTHASE; MYCOLIC ACID; SYNTHETASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; BIOSYNTHESIS; CONFERENCE PAPER; CRYSTAL STRUCTURE; ENZYME SYNTHESIS; HUMAN; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0347722525     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2003.08.019     Document Type: Conference Paper

References (50)

1. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6: 107-12.
2. Mitchison DA. Treatment of tuberculosis. The Mitchell lecture 1979, J. R. Coll. Physicians Lond 1980; 14: 91-9.
3. Girling DJ. In: Ratledge C, Stanford J, Grange JM, editors. The biology of the mycobacteria, volume 3: clinical aspects of mycobacterial disease London: Academic; 1989.
4. Duncan K, Sacchettini JC. Approaches to tuberculosis drug development. In: Hatfull GF, Jacobs WRJ, editors. Molecular genetics of mycobacteria. Washington DC: ASM Press; 2000. p. 297-307.
5. Mckinney JD, Jacobs WRJ, Bloom BR. Persisting problems in tuberculosis. In: Krause RM, editor. Emerging infections. New York: Academic Press; 1998. p. 51-146.
6. Hönerzu Bentrup K, Russell DG. Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol 2001; 9: 597-605.
7. Agerton TB, Valway SE, Blinkhom RJ, Shilkret KL, Reves R, Schluter WW., et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999; 29: 85-92; discussion 93-85.
8. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-6.
9. McKinney JD, zu Bentrup KH, Munoz-Elias EJ, Miczak A, Chen B, Chan WT., et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-8.
10. Graham JE, Clark-Curtiss JE. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci USA 1999; 96: 11554-9.
11. Cox JS, Chen B, McNeil M, Jacobs Jr. WR. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999; 402: 79-83.
12. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999; 34: 257-67.
13. Dubnau E, Chan J, Raynaud C, Mohan VP, Laneelle MA, Yu K., et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol 2000; 36: 630-7.
14. Glickman MS, Cox JS, Jacobs Jr. WR. A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5: 717-27.
15. Segal W. In: Kubica GP, Wayne LG, editors. The Mycobacteria: a source book. New York: Dekker, 1984.
16. Wheeler PR, Ratledge C. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection and control. Washington DC: ASM Press; 1994. p. 353-85.
17. Höner Zu Bentrup K, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999; 181: 7161-7.
18. Sharma V, Sharma S, Höner zu Bentrup K, McKinney JD, Russell DG, Jacobs Jr. WR., et al. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 2000; 7: 663-8.
19. Bennett MJ, Schlunegger MP, Eisenberg D. 3D domain swapping: a mechanism for oligomer assembly. Protein Sci 1995; 4: 2455-68.
20. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR., et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.
21. Luttik MA, Kotter P, Salomons FA, van der Klei IJ, van Dijken JP, Pronk JT. The Saccharomyces cerevisiae ICL2 gene encodes a mitochondrial 2-methylisocitrate lyase involved in propionyl-coenzyme A metabolism. J Bacteriol 2000; 182: 7007-13.
22. Brock M, Darley D, Textor S, Buckel W. 2-Methylisocitrate lyases from the bacterium Escherichia coli and the filamentous fungus Aspersillus nidulans: characterization and comparison of both enzymes. Eur J Biochem 2001; 268: 3577-86.
23. Horswill AR, Escalante-Semerena JC. Propionate catabolism in Salmonella typhimurium LT2: two divergently transcribed units comprise the prp locus at 8. 5 centisomes, prpR encodes a member of the sigma-54 family of activators, and the prpBCDE genes constitute an operon. J Bacteriol 1997; 179: 928-40.
24. Britton KL, Abeysinghe IS, Baker PJ, Barynin V, Diehl P, Langridge SJ., et al. The structure and domain organization of Escherichia coli isocitrate lyase. Acta Crystallogr D Biol Crystallogr 2001; 57: 1209-18.
25. Britton K, Langridge S, Baker PJ, Weeradechapon K, Sedelnikova SE, De Lucas JR., et al. The crystal structure and active site location of isocitrate lyase from the fungus Aspersillus nidulans. Structure Fold Des 2000; 8: 349-62.
26. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, zu Bentrup KH. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 2003; 278: 1735-43.
27. Howard BR, Endrizzi JA, Remington SJ. Crystal structure of Escherichia coli malate synthase G complexed with magnesium and glyoxylate at 2.0 A resolution: mechanistic implications. Biochemistry 2000; 39: 3156-68.
28. Remington SJ. Structure and mechanism of citrate synthase. Curr Top Cell Regul 1992; 33: 209-29.
29. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T., et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.
30. Barry III CE, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA., et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res 1998; 37: 143-79.
31. Grogan DW, Cronan Jr. JE. Cyclopropane ring formation in membrane lipids of bacteria. Microbiol Mol Biol Rev 1997; 61: 429-41.
32. Minnikin DE. The biology of mycobacteria. In: Ratledge C, Stanford J, editors. The biology of mycobacteria. San Diego: Academic Press; 1982. p. 95-184.
33. Yuan Y, Lee RE, Besra GS, Belisle JT, Barry III CE. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995; 92: 6630-4.
34. Yuan Y, Crane DC, Musser JM, Sreevatsan S, Barry III CE. MMAS-1, the branch point between cis-and trans-cyclopropane-containing oxygenated mycolates in Mycobacterium tuberculosis. J Biol Chem 1997; 272: 10041-9.
35. George KM, Yuan Y, Sherman DR, Barry III CE. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J Biol Chem 1995; 270: 27292-8.
36. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
37. Glickman MS, Cahill SM, Jacobs Jr. WR. The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid transcyclopropane synthetase. J Biol Chem 2001; 276: 2228-33.
38. Wang AY, Grogan DW, Cronan Jr. JE. Cyclopropane fatty acid synthase of Escherichia coli: deduced amino acid sequence, purification, and studies of the enzyme active site. Biochemistry 1992; 31: 11020-8.
39. Huang C, Smith CV, Glickman M, Jacobs Jr. WR, Sacchettini JC. Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J Biol Chem 2002; 277: 11559-69.
40. Klimasauskas S, Kumar S, Roberts RJ, Cheng X. Hhal methyltransferase flips its target base out of the DNA helix. Cell 1994; 76: 357-69.
41. Djordjevic S, Stock AM. Crystal structure of the chemotaxis receptor methyltransferase CheR suggests a conserved structural motif for binding S-adenosylmethionine. Structure 1997; 5: 545-58.
42. Schluckebier G, O'Gara M, Saenger W, Cheng X. Universal catalytic domain structure of AdoMet-dependent methyltransferases. J Mol Biol 1995; 247: 16-20.
43. Cheng X, Roberts RJ. AdoMet-dependent methylation, DNA methyltransferases and base flipping. Nucleic Acids Res 2001; 29: 3784-95.
44. Yuan Y, Barry III CE. A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1996; 93: 12828-33.
45. Schluckebier G, Labahn J, Granzin J, Saenger WM. TaqI: possible catalysis via cation-pi interactions in N-specific DNA methyltransferases. Biol Chem 1998; 379: 389-400.
46. Pogolotti Jr. AL, Ono A, Subramaniam R, Santi DV. On the mechanism of DNA-adenine methylase. J Biol Chem 1988; 263: 7461-4.
47. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature 1994; 368: 354-8.
48. Dougherty DA. Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996; 271: 163-8.
49. Yuan Y, Mead D, Schroeder BG, Zhu Y, Barry III CE. The biosynthesis of mycolic acids in Mycobacterium tuberculosis. Enzymatic methyl(ene) transfer to acyl carrier protein bound meromycolic acid in vitro. J Biol Chem 1998; 273: 21282-90.
50. Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature 2001; 412: 83-6.